IP Library Granted Patent US 12,227,522
Granted Patent B2
US 12,227,522 · App. 18/255,969 · Granted Feb 18, 2025

Synthesis of structural analogs of largazole and associated compounds

Inventors: Robert M. Williams (Ft. Collins, CO); Sivanagireddy Koti (Ft. Collins, CO); Subhadip De (Ft. Collins, CO); Anil M. Shelke (Ft. Collins, CO); Ryan E. Cerbone (Ft. Collins, CO); Nobuyoshi Yasuda (Ft. Collins, CO)
Assignees: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION; CETYA THERAPEUTICS, INC.
C07D513/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,227,522
App. No.
18/255,969
Granted
Feb 18, 2025
Kind
B2
Abstract

Disclosed are various synthetic methods to prepare structural analogs of largazole and derivatives thereof. One structural analog is an amide isostere of largazole. Another structural analog replaces the thiazole ring of largazole with a pyridine moiety or an oxazole moiety. Also disclosed are various intermediate compounds obtained when preparing structural analogs of largazole and derivatives thereof, including macrocycle analogs having an alcohol functionality.

Claims (78)

1. A method for preparing a compound of formula (III):

the method comprising:

reacting a compound of formula (I):

with an activating agent selected from C 1 -C 20 linear or branched alkyl-sulfonyl halide, substituted alkyl-sulfonyl halide, arylsulfonyl halide, substituted arylsulfonyl halide, halo-phosphite, or a halogenating reagent, thereby forming a compound of formula (II):

and reacting the compound of formula (II) with a nucleophile comprising an R 1 group, thereby forming the compound of formula (III);

wherein:

X is O or NH;

Ar is thiazolyl, pyridinyl, or oxazolyl;

R 1 is R 2 COS, R 3 S, or R 4 R 5 N;

R 2 , R 3 , R 4 , and R 5 independently are hydrogen, C 1 -C 24 linear alkyl, C 1 -C 24 linear alkyl substituted with one or more aryl or heteroaryl in any position, C 1 -C 24 branched alkyl, C 1 -C 24 branched alkyl substituted with one or more aryl or heteroaryl in any position, C 3 -C 24 cyclic alkyl, C 3 -C 24 cyclic alkyl substituted with one or more aryl or heteroaryl in any position, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, aryl, heteroaryl, diphenyl methyl, or triphenylmethyl; and

L is a leaving group selected from C 1 -C 24 linear or branched carbon sulfonate, substituted C 1 -C 24 linear or branched sulfonate, arylsulfonate, substituted arylsulfonate, heteroarylsulfonate, substituted heteroarylsulfonate, phosphate, or halogen.

2. A method for preparing a compound of formula (III):

the method comprising:

reacting a compound of formula (II) with a nucleophile comprising an R 1 group:

wherein:

X is O or NH;

Ar is thiazolyl, pyridinyl, or oxazolyl;

R 1 is R 2 COS, R 3 S, or R 4 R 5 N;

R 2 , R 3 , R 4 , and R 5 independently are hydrogen, C 1 -C 24 linear alkyl, C 1 -C 24 linear alkyl substituted with one or more aryl or heteroaryl in any position, C 1 -C 24 branched alkyl, C 1 -C 24 branched alkyl substituted with one or more aryl or heteroaryl in any position, C 3 -C 24 cyclic alkyl, C 3 -C 24 cyclic alkyl substituted with one or more aryl or heteroaryl in any position, C 2 -C 24 alkenyl, C 2 -C 24 alkynyl, aryl, heteroaryl, diphenyl methyl, triphenylmethyl; and

L is a leaving group selected from C 1 -C 24 linear or branched carbon sulfonate, substituted C 1 -C 24 linear or branched sulfonate, arylsulfonate, substituted arylsulfonate, heteroarylsulfonate, substituted heteroarylsulfonate, phosphate, or halogen; and

producing the compound of formula (II) from a compound of formula (IX):

by converting OR 6 of the compound of formula (IX) into the leaving group L;

wherein R 6 is H or a suitable alcohol protecting group.

3. The method of claim 2 , wherein converting OR 6 into the leaving group L comprises:

when R 6 is the suitable alcohol protecting group, deprotecting the suitable alcohol protecting group to provide the compound of formula (IX) where R 6 is H; and

reacting the compound of formula (IX) where R 6 is H with an activating agent selected from C 1 -C 20 linear or branched alkyl-sulfonyl halide, substituted alkyl-sulfonyl halide, arylsulfonyl halide, substituted arylsulfonyl halide, halo-phosphite, or a halogenating reagent.

4. The method of claim 2 , wherein the compound of formula (IX) is a compound of formula (I):

and the method comprises reacting the compound of formula (I) with an activating agent selected from C 1 -C 20 linear or branched alkyl-sulfonyl halide, substituted alkyl-sulfonyl halide, arylsulfonyl halide, substituted arylsulfonyl halide, halo-phosphite, or a halogenating reagent, thereby forming the compound of formula (II).

5. The method of claim 2 , wherein the compound of formula (IX) is a compound of formula (I-a), (I-b), or (I-c):

6. The method of claim 1 , wherein L is OMs, OTs, OTf, 2,2,2-trifluoroethanesulfonate, n-octanesulfonate, benzenesulfonate, OP(═O)(OMe) 2 , OP(═O)(OEt) 2 , OP(═O)(OPh) 2 , I, Br, Cl or F.

7. The method of claim 1 , wherein Ar is:

8. The method of claim 1 , wherein the nucleophile is thiooctanoic acid, such that the compound of formula (III) is a compound of formula (XXV):

9. The method of claim 8 , wherein:

X is NH and Ar is:

such that the compound of formula (III) is a compound of formula (1):

X is O and Ar is:

such that the compound of formula (III) is a compound of formula (2):

 or

X is O and Ar is:

such that the compound of formula (III) is a compound of formula (3):

10. The method of claim 2 , wherein the method further comprises producing a compound of formula (I) or the compound of formula (IX) from one or more reactions comprising:

a compound of formula (IV):

a compound of formula (V):

and a compound of formula (VI):

wherein:

R 6 is H or a suitable alcohol protecting group,

R 8 , R 10 , and R 12 independently are H, a suitable amine protecting group, or a chiral group,

R 7 , R 9 , and R 11 independently are H, an alkali metal ion, an alkaline earth metal ion, or a suitable carboxylic acid protecting group;

optionally wherein the suitable carboxylic acid protecting group is selected from C 1 -C 6 linear or branched alkyl, C 1 -C 6 linear or branched alkyl substituted with one or more aryl or heteroaryl in any position, or alkylsilyl;

optionally wherein the C 1 -C 6 linear or branched alkyl, or the C 1 -C 6 linear or branched alkyl substituted with one or more aryl or heteroaryl in any position, is selected from methyl, ethyl, propyl, isopropyl, allyl, butyl, 2-butyl, tert-butyl, benzyl, or substituted benzyl; and

optionally wherein the alkylsilyl is 2-(trimethylsilyl) ethyl.

11. The method of claim 10 , wherein:

the compound of formula (IV) is reacted with the compound of formula (V) via condensation to form a compound of formula (VII):

the compound of formula (VII) is reacted with the compound of formula (VI) via amidation to form a compound of formula (VIII):

and the compound of formula (VIII) is reacted by amidating ring closure to form the compound of formula (IX) or a compound of formula (I)

12. The method of claim 11 , wherein:

R 6 is H or a suitable alcohol protecting group;

in reacting the compound of formula (IV) with the compound of formula (V): R 8 is H, and when X is N, the N is neutral or positively charged; R 7 is a suitable carboxylic acid protecting group; R 10 is a suitable amine protecting group; and R 9 is H, an alkali metal ion, or an alkaline earth metal ion;

in reacting the compound of formula (VI) with the compound of formula (VII): R 7 is a suitable carboxylic acid protecting group; R 10 is H, and optionally R 10 is attached to a positively charged nitrogen atom; R 11 is H, an alkali metal ion, or an alkaline earth metal ion; and R 12 is a suitable amine protecting group; and

in reacting the compound of formula (VIII) by amidating ring closure: R 6 is H or a suitable alcohol protecting group; R 7 is H, an alkali metal ion, or an alkaline earth metal ion; and R 12 is H, and optionally R 12 is attached to a positively charged nitrogen atom.

13. The method of claim 10 , wherein X is NH, and the method further comprises producing the compound of formula (IV) by:

reacting via imine formation a compound of formula (X):

with a chiral auxiliary of formula (XI-a):

Y—NH 2   (XI-a)

to form a compound of formula (XII):

reacting the compound of formula (XII) via nucleophilic addition with a compound of formula (XIII):

to form the compound of formula (IV) where X is NH and R 8 is chiral group Y:

and cleaving the N—Y bond to form the compound of formula (IV) where R 8 is H, and when X is N, the N is neutral or positively charged,

wherein:

Y is a chiral group sufficient to effect a diastereoselective nucleophilic addition of the compound of formula (XIII) to the compound formula (XII) to form the compound of formula (IV) as a majority product where R 8 is chiral group Y,

R 6 is a suitable alcohol protecting group,

R 7 is a suitable carboxylic acid protecting group;

optionally wherein the carboxylic acid protecting group is selected from C 1 -C 6 linear or branched alkyl, C 1 -C 6 linear or branched alkyl substituted with one or more aryl or heteroaryl in any position, or alkylsilyl;

optionally wherein the C 1 -C 6 linear or branched alkyl, or the C 1 -C 6 linear or branched alkyl substituted with one or more aryl or heteroaryl in any position, is selected from methyl, ethyl, propyl, isopropyl, allyl, butyl, 2-butyl, tert-butyl, benzyl, or substituted benzyl; and

optionally wherein the alkylsilyl is 2-(trimethylsilyl) ethyl; and

R 13 is H, a halide, or a metal comprising Li, Na, K, ZnBr, ZnCl, CuCl, CuBr, Cul, Cu, or any combination thereof.

14. The method of claim 13 , wherein Y is R 14 —S═O such that the chiral auxiliary is of formula (XI-b):

wherein R 14 is tert-butyl such that the compound of formula (XI-b) is (R)-tert-butanesulfinamide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2023
From: WILLIAMS (LEGAL REPRESENTATIVE OF DECEASED INVENTOR ROBERT M. WILLIAMS), JILL
To: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
Reel/Frame 064133/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2023
From: KOTI, SIVANAGIREDDY; DE, SUBHADIP; SHELKE, ANIL M.; YASUDA, NOBUYOSHI
To: CETYA THERAPEUTICS, INC.
Reel/Frame 064133/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2023
From: CERBONE, RYAN E.
To: COLORADO STATE UNIVERSITY RESEARCH FOUNDATION; CETYA THERAPEUTICS, INC.
Reel/Frame 064133/0301 →
Continuity (2)
Provisional Application 63128273 · Dec 21, 2020
Related Publication 20240059709A1 · Feb 22, 2024
References Cited (118)
US 4456592A · Okumura et al. · 1984 [cited by applicant]
US 5846933A · Korngold et al. · 1998 [cited by applicant]
US 6509315B1 · Joullie et al. · 2003 [cited by applicant]
US 8217076B2 · Williams et al. · 2012 [cited by applicant]
US 8513290B2 · Williams et al. · 2013 [cited by applicant]
US 9186402B2 · Williams et al. · 2015 [cited by applicant]
US 10538534B2 · Williams et al. · 2020 [cited by applicant]
US 10676504B2 · Williams et al. · 2020 [cited by applicant]
US 20050119169A1 · Deslongchamps et al. · 2005 [cited by applicant]
US 20070129289A1 · Joullie et al. · 2007 [cited by applicant]
US 20120264794A1 · Williams et al. · 2012 [cited by applicant]
US 20140080802A1 · Holson et al. · 2014 [cited by applicant]
US 20140093449A1 · Williams et al. · 2014 [cited by applicant]
US 20140243501A1 · Jiang et al. · 2014 [cited by applicant]
US 20150010541A1 · Liu et al. · 2015 [cited by applicant]
US 20180044376A1 · Williams et al. · 2018 [cited by applicant]
JP 03141296A · 1991 [cited by applicant]
JP 2003505417A · 2003 [cited by applicant]
JP 2009507065A · 2009 [cited by applicant]
JP 2013528182A · 2013 [cited by applicant]
JP 2013532132A · 2013 [cited by applicant]
JP 2014523857A · 2014 [cited by applicant]
WO WO2007061939A2 · 2007 [cited by applicant]
WO WO2007100385A2 · 2007 [cited by applicant]
WO WO2009032352A1 · 2009 [cited by applicant]
WO WO2009126315A2 · 2009 [cited by applicant]
WO WO2010009334A1 · 2010 [cited by applicant]
WO WO2011146918A2 · 2011 [cited by applicant]
WO WO2015183897A1 · 2015 [cited by applicant]
WO WO2016144665A1 · 2016 [cited by applicant]
WO WO2016144814A1 · 2016 [cited by applicant]
WO WO2022140144A1 · 2022 [cited by applicant]
International Preliminary Report on Patentability, dated Jun. 13, 2023, corresponding to International Application No. PCT/US2021/063719, (from which the present application claims priority,) 8 pp. [cited by applicant]
International Search Report and Written Opinion, dated May 5, 2022, corresponding to International Application No. PCT/US2021/063719, (from which the present application claims priority,) 16 pp. [cited by applicant]
Pubchem-SID:53837011 Deposit Date: Oct. 6, 2008 {Oct. 6, 2008) pp. 1-5; p. 2. (4 pages). [cited by applicant]
Ren et al. (2008) “Total Synthesis of Largazole,” Synlett., vol. 15. pp. 2379-2383; DOI: 10.1055/s-2008-1078270. (5 pages). [cited by applicant]
Ying (2010) “Total Syntheses and Biological Studies of Largazole and Brasilibactin A., II. Stereoselective Synthesis of 2,6-Cis- and 2,6-Trans-Piperidines through an Organocatalytic Aza-Michael Reaction,” Dissertation s… [cited by applicant]
“Can child leukemia be prevented?”, https://www.cancer.org/cancer/leukemia-in-children/causes-risks-prevention/prevention.html, last revised Feb. 3, 2016, accessed Oct. 25, 2018 (Year: 2016). [cited by applicant]
Avenoza et al. (2001) “Enantioselective synthesis of (S)- and (R)-methylserines: application to the synthesis of (S)- and (R)-N-Boc-N,O-isopropylidene-amethylserinals,” Tetrahedron: Asymmetry 12(6):949-957. [cited by applicant]
Berge et al. (1977) “Pharmaceutical salts,” J. Pharm. Sci. 66: 1-19. [cited by applicant]
Bolden et al. (2006) “Anticancer activities of histone deacetylase inhibitors,” Nat. Rev. Drug Discovery 5:769-784. [cited by applicant]
Bowers et al. (2008) “Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase Inhibitor,” J Am Chem Soc 130:11219-22. [cited by applicant]
Bowers et al. (Feb. 2009) “Synthesis and Histone Deacetylase Inhibitory Activity of Largazole Analogs: Alteration of the Zinc-Binding Domain and Macrocyclic Scaffold,” Org. Letters 11(6) 1301-1304. [cited by applicant]
Bowers et al. (Mar. 2009) “Synthesis and Conformation-Activity Relationships of the Peptide Isosteres of FK228 and Largazole,” J. Am. Chem. Soc. 131, 2900-2905. [cited by applicant]
Bradner (2010) “Chemical Phylogenetics of Histone Deacetylases,” Nat. Chem Biol. 6(3):238-243. [cited by applicant]
Burger's Medicinal Chemistry and Drug Discovery (1995, Manfred E. Wolff ed., 5th ed. 172-178, 929-932). [cited by applicant]
Chen et al. (2003) “Total Synthesis of the Depsipeptide FR-901375,” J Org Chem 68:8902-8905. [cited by applicant]
Chen et al. (2018) “Process Development and Scale-up Total Synthesis of Largazole, a Potent Class I Histone Deacetylase Inhibitor,” Org. Process, Res. & Dev., 22, 190-199. [cited by applicant]
Clausen et al. (2015) “Modular Synthesis and Biological Activity of Pyridyl-based Analogs of the Potent Class 1 Histone Deacetylase Inhibitor Largazole,” Bioorg. & Med. Chem. 23:5061-5074. [cited by applicant]
Cleve, Trip Report for 9th Tetrahedron Symposium, Berkeley, CA Klos, Jul. 22-25, 2008, “Discovery and Optimization of Diamine Analogues as Potent Inhibitors of Leukotriene A4 Hydrolase.” [cited by applicant]
Freireich et al. (1966) “Quantitative comparison to toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man,” Cancer Chemother Rep 50:219. [cited by applicant]
Furumai et al. (2001) “Potent Histone Deacetylase Inhibitors Built From Trichostatin A and Cyclic Tetrapeptide Antibiotics Including Trapoxin,” PNAS USA 98:87-92. [cited by applicant]
Ghosh et al. (2008) “Enantioselective Total Synthesis of ( + )-Largazole, a Potent Inhibitor of Histone Deacetylase,” Org. Lett. 10:3907-3909. [cited by applicant]
Greshock et al. (2008) “Improved Total Synthesis of the Potent HDAC Inhibitor FK228 (FR-901228),” Org Lett 10:613-616. [cited by applicant]
Grozinger et al. (1999) “Three proteins define a class of human histone deacetylases related to yeast Hdal p,” Proc. Nat. Acad. Sci. USA 96:4868-4873. [cited by applicant]
Guerra-Bubb et al. (2013) “Synthesis and HDAC inhibitory activity of isosteric thiazoline-oxazole largazole analogs,” Bioorganic & Medicinal Chemistry Letters, 23(21), pp. 6025-6028. [cited by applicant]
Han et al. (2014) “Spiroacetal Formation through Telescoped Cycloaddition and Carbon-Hydrogen Bond Functionalization: Total Synthesis of Bistramide A,” Angew. Chem. Int. Ed. 53, 11075-11078. [cited by applicant]
Handbook of Pharmaceutical Salts. Properties, Selection, and Use (P. Heinrich Stahl and C. Wermuth, Eds., Verlag Helvetica Chica Acta, Zurich, Switzerland (2002)). [cited by applicant]
Hong et al. (2012) “Largazole: From discovery to broad-spectrum therapy,” Natural Products Reports, 29, 449-56. [cited by applicant]
Jeanguenat et al. (1991) “Stereoselective chain elongation at C-3 of cysteine through 2,3-dihydrothiazoles, without racemization. Preparation of 2-amino-5-hydroxv-3-mercaptoalkanoic acid derivatives,” J Chem Soc, Perkin… [cited by applicant]
Johnstone (2002) “Histone deacetylase inhibitors: novel drugs for the treatment of cancer,” Nature Rev. Drug Disc. 1:287-299. [cited by applicant]
Katsura et al. (1994) “Studies on antiulcer drugs. 7. 2-Guanidino-4-pyridylthiazoles as histamine H2-receptor antagonists with potent gastroprotective effects against nonsteroidal antiinflammatory drug-induced injury,” … [cited by applicant]
Lange et al. (1999) “A new mild method for the synthesis of amidines,” Tetrahedron Lett. 40:7067-7070. [cited by applicant]
Li et al. (1996) “Total Synthesis of the Antitumor depsipeptide FR-901, 228,” J Am Chem Soc 118:7237-7238. [cited by applicant]
Liu et al. (2010) “Anticolon Cancer Activity of Largazole, a Marine-Derived Tunable Histone Deacetylase Inhibitor,” Journal of Pharmacology and Experimental Therapeutics, 335, 351-361. [cited by applicant]
Marsault et al. (2006) “Discovery of a New Class of Macrocyclic Antagonists to the Human Motilin Receptor,” Journal of Medicinal Chemistry pp. C-D. [cited by applicant]
Masuoka et al. (2001) “Spiruchostatins A and B, novel gene expression-enhancing substances produced by [cited by applicant]
Miller et al. (2003) “Histone deacetylase inhibitors,” J. Med. Chem. 46:5097-5116. [cited by applicant]
Minucci et al. (2006) “Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer,” Nature Rev. Cancer 6:38-51. [cited by applicant]
Moradei et al. (2005) “Histone deacetylase inhibitors: latest developments, trends and prospects,” Curr. Med. Chem. Anti-Cancer Agents 5:529-560. [cited by applicant]
Mulqueen et al. (1993) “Synthesis of the thiazoline-based siderophore (S)-desferrithiocin,” Tetrahedron 49:5359-5364. [cited by applicant]
Nasveschuk et al. (2008) “A Concise Total Synthesis of Largazole, Solution Structure, and Some Preliminary Structure Activity Relationships,” Org. Lett. 10:3595-3598. [cited by applicant]
Nishino et al. (2003) “Cyclic tetrapeptides bearing a sulfhydryl group potently inhibit histone deacetylases,” Org Lett 5:5079-5082. [cited by applicant]
Patani et al. (1996) “Bioisosterism: A Rational Approach in Drug Design,” Chem. Rev. 96:3147-3176. [cited by applicant]
Phillips et al. (2000) “Synthesis of Functionalized Oxazolines and Oxazoles with DAST and Deoxo-Fluor,” Org Lett 2(8): 1165-1168. [cited by applicant]
Pilon et al. (2015) “Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere,” Cancer Chemother Pharmacol. 75(4): 671-682. [cited by applicant]
Quintas-Cardama et al. (2011) “Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia,” Leukemia, 25, 226-35. [cited by applicant]
Reiner et al. (2002) “Non-covalent thrombin inhibitors featuring p3-heterocycles with PI-monocyclic arginine surrogates,” Bioorg Med Chem Lett 12(8):1203-1208. [cited by applicant]
Salvador et al. (2014) “Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties,” ACS Medicinal Chemistry Letters, 5, 905-10. [cited by applicant]
Scientific Tables, Geigy Pharmaceuticals, Ardley, N.Y., (1970) 537. [cited by applicant]
Seiser et al. (2008) “Synthesis and Biological Activity of Largazole and Derivatives,” Angew. Chem. Int. Ed. 47:6483-6485. [cited by applicant]
Shigematsu et al. (1994) “A novel antitumor bicycle depsipeptide produced by Chromobacterium violaceum No. 968,” J. Antibiot. 47:311-314. [cited by applicant]
Smith et al. (2003) “Enantioselective synthesis of alphamethyl-D-cysteine and lanthionine building blocks via alpha-methyl-D-serine-beta-lactone,” Org. Lett. 5:1035-1037. [cited by applicant]
Somech et al. (2004) “Histone deacetylase inhibitors—a new tool to treat cancer,” Cancer Treat. Rev. 30:461. [cited by applicant]
Souto et al. (2010) “Synthesis and Biological Characterization of the Histone Deacetylase Inhibitor Largazole and C7-Modified Analogues,” Journal of Medicinal Chemistry, 53, 4654-67. [cited by applicant]
Sun et al. (2018) “Radical-Mediated Thiol-Ene Strategy: Photoactivation of Thiol Containing Drugs in Cancer Cells,” Angew. Chem. Int. Ed. 57, 15832-15835. [cited by applicant]
Taori et al. (2008) “Structure and Activity of Largazole, a Potent Antiproliferative Agent from the Floridian Marine Cyanobacterium [cited by applicant]
Taunton et al. (1996) “A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p,” Science 272:408-411. [cited by applicant]
Townsend et al. (2007) “The bicyclic depsipeptide family of his tone deacetylase inhibitors,” in Chemical Biology; Schreiber, S.L., et al. Eds.Wiley-VCR Verlag GmbH & Co. 693-720. [cited by applicant]
Ueda et al. (1994) “Action of FR901228, a Novel Antitumor Bicyclic Depsipeptide Produced by Chromobacterium violaceum No. 968, on Ha-ras Transformed NIH3T3 Cells,” Biosci. Biotech. Biochem., 58 (9), 1579-1583. [cited by applicant]
Ueda et al. (1994) “FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968 III. Antitumor activities on experimental tumors in mice,” J. Antibiot. 47:315-323. [cited by applicant]
Ueda et al. (1994) “FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activi… [cited by applicant]
Vanommeslaeghe et al. (Jul. 2005) “DFT-based Ranking of Zink-chelating Groups in Histone Deacetylase Inhibitors,” Bioorg. Med. Chem. 13:6070-6082. [cited by applicant]
Vanommeslaeghe et al. (May 2005) “Theoretical study revealing the functioning of a novel combination of catalytic motives in Histone Deacetylase,” Bioorg. Med. Chem. 13:3987-3992. [cited by applicant]
Videnov et al. (1996) “Synthesis of Naturally Occurring, Conformationally Restricted Oxazole and Thiazole Containing Di- and Tripeptide Mimetics,” Angew Chem Int Ed Eng 35:1503-1506. [cited by applicant]
Ying et al. (Aug. 2008) “Synthesis and Activity of Largazole Analogues with Linker and Macrocycle Modification,” Organic Letters 10(18):4021-4024. [cited by applicant]
Ying et al. (May 2008) “Total Synthesis and Molecular Target of Largazole, a Histone Deacetylase Inhibitor,” J. Am. Chem. Soc. 130:8455-8459. [cited by applicant]
Yoshida et al. (Oct. 1990) “Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A,” J. Biol. Chem. 265:17174. [cited by applicant]
Yoshida et al. (Sep. 1990) “Structural Specificity for Biological Activity of Trichostatin A, A Specific Inhibitor of Mammalian Cell Cycle with Potent Differentiation-Inducing Activity in Friend Leukemia Cells,” J. Anti… [cited by applicant]
Yurek-George (2007) “The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor,” J. Med. Chem. 50:5720-5726. [cited by applicant]
Yurek-George et al. (2004) “Total synthesis of spiruchostatin A, a potent histone deacetylase inhibitor,” J Am Chem Soc 126: 1030-1031. [cited by applicant]
Zawilska et al. (2013) “Prodrugs: A challenge for the drug development,” Pharmacological Reports, 65, 1-14. [cited by applicant]
Zhang et al. (Nov. 2019—Available online Sep. 4, 2019) “A fluorine scan on the Zn2+-binding thiolate side chain of HDAC inhibitor largazole: Synthesis, biological evaluation, and molecular modeling,” Eur. J. Med. Chem.,… [cited by applicant]
Zhao et al. (2017) “Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors,” Israel Journal of Chemistry, 57, 319-330. [cited by applicant]
Akoto et al. (May 2019) “Concise Seven-Membered Oxepene/Oxepane Synthesis—Structural Motifs in Natural and Synthetic Products,” Synthesis 51, 3529-3535. [cited by applicant]
Awakura (2000) “Synthetic Studies on Pectenotoxins: Synthesis of the Common C8-C18 THF Fragment,” Synlett, 12, 1733-1736. [cited by applicant]
Cao et al. (2011) “Caspase-3 controlled assembly of nanoparticles for fluorescence turn on,” Chemical Communications, 47(37), 10320-10322. [cited by applicant]
Caron et al. (2010) “Versatile Strategy to Access Tricycles Related to Quassinoids and Triterpenes,” Org. Lett., 12, 508-511. [cited by applicant]
Crimmins et al. (2000) “Titanium Enolates of Thiazolidinethione Chiral Auxiliaries: Versatile Tools for Asymmetric Aldol Additions,” Org. Lett. 2, 775-777. [cited by applicant]
Crimmins et al. (2001) “Asymmetric Aldol Additions: Use of Titanium Tetrachloride and (−)-Sparteine for the Soft Enolization of N-Acyl Oxazolidinones, Oxazolidinethiones, and Thiazolidinethiones,” J. Org. Chem. 66, 894-… [cited by applicant]
Pellissier (2018) “Recent developments in the asymmetric Reformatsky-type reaction,” Beilstein J. Org. Chem., 14, 325-344. [cited by applicant]
Pierry (2011) “Synthesis of fluorinated pseudopeptides: metal mediated reversal of stereochemistry in diastereoselective addition of organometallic reagents to N-(tert-butanesulfinyl)-a-fluoroenimines,” Org. Biomol. Che… [cited by applicant]
Tungen et al. (2015) “Stereoselective synthesis of maresin 1,” Tetrahedron Lett. 56, 1843-1846. [cited by applicant]
U.S. Appl. No. 15/555,792, filed Sep. 5, 2017. [cited by applicant]
Borgini et al. (2020) “Synthesis and Antiproliferative Activity of Nitric Oxide-Donor Largazole Prodrugs,” ACS Med. Chem. Lett. 11(5): 846-851. [cited by applicant]
Bowers et al. (Feb. 2009) “Synthesis and Conformation—Activity Relationships of the Peptide Isosteres of FK228 and Largazole,” J. Am. Chem. Soc. 131: 2900-2905. [cited by applicant]
European Search Report (Partial) issued in EP 21911912.0 on Nov. 6, 2024. [cited by applicant]
Kim et al. (2017) “Synthesis and biological evaluation of largazole zinc-binding group analogs”, Bioorganic & Medicinal Chemistry 25(12): 3077-3086. [cited by applicant]